Lavipharm
Focus: Lavipharm is a public French biotech company focused on small-molecule cardiovascular drugs, built on a portfolio of legacy branded generics and approaching-LOE assets. The company derives 34% of revenue from ZESTRIL (lisinopril), a mature ACE inhibitor facing patent expiration.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Lavipharm
AI assessmentNot HiringNo open roles listed right now. Follow Lavipharm to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthWatch
Pipeline
Early-stage
0 total
LOE Risk
1 imminent
VALCYTE
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$4M Part DDeclining
LOE Approaching
Core revenue driver at 34% of total; patent expiration imminent, creating critical cash flow cliff.
Help build intelligence for Lavipharm
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.